All In Biotech

NDA 008762 · Viatris

Dilantin-125

Phenytoin · Oral · Anti-epileptic Agent

Last checked: Nov 19, 2026Latest source record: Mar 3, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1953

Jan 6, 1953

Approved uses

1

Original approval plus efficacy supplements

Registered trials

113

17 Phase 3, 6 recruiting

FAERS reports

20,902

18,748 serious, 2,991 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 24, 2024.

Phenytoin is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. Phenytoin is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. ( 1 )

Mechanism: The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 6, 1953 Original approval · Type 2 - New Active Ingredient
2 products under this application
  • DILANTIN-125 · PHENYTOIN 125MG/5ML · SUSPENSION, ORAL · Prescription · TE AB
  • DILANTIN-30 · PHENYTOIN 30MG/5ML · SUSPENSION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Phenytoin" as an intervention, any sponsor and status, largest first.

All 113 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,771
  • drug interaction1,580
  • seizure1,426
  • toxicity to various agents1,372
  • convulsion1,260
  • off label use1,140
  • status epilepticus812
  • stevens-johnson syndrome771
  • pyrexia686
  • fall618
  • dizziness606
  • drug reaction with eosinophilia and systemic symptoms603

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004569
2005621
2006433
2007499
2008682
2009659
2010895
20111,213
20121,038
20131,000
2014907
2015989
2016929
20171,102
20181,201
20191,250
20201,232
20211,121
20221,114
20231,131
2024988
2025867
2026462

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dilantin-125 (Phenytoin)

2024 spending

$151K

Beneficiaries

86

428 claims

Per beneficiary

$1,756

$0.81 per unit

View as table
YearSpending
2020$9,904
2021$181,085
2022$197,071
2023$186,396
2024$150,995

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,037 on PubMed

Sponsor: Viatris · Also marketed as Dilantin-30

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.